BIODESIX for BIODESIX
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report | Oct 18, 2019 | $59,235 | Replaced |
| 3rd Quarter - Termination (this page) | Jun 27, 2020 | $60,000 | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Discussion draft to reform Section 101 of the Patent Act concerning patent eligibility.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATIE JONES | — |
Medicare/Medicaid MMM
Implementation of Protecting Access to Medicare Act of 2014 (P.L. 113-93). Payment of laboratory tests in surprise billing legislation (S.1895; H.R. 3630). Update packaging policy for protein-based tests (CY 2018 OPPS/ASC final rule). Preserve current laboratory date of service policy (CY 2020 OPPS proposed rule).
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATIE JONES | — |
Medical/Disease Research/Clinical Labs MED
Regulation of laboratory developed tests (Verifying Accurate, Leading-edge IVCT Development (VALID) Act discussion draft).
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATIE JONES | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.